Adult COVID-19 Vaccines
Closed Solicitation Posted
This opportunity was awarded. See its 3 award notices in the notice history.
- Solicitation number
- 75D301-22-R-72483
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention seeks to award indefinite delivery/indefinite quantity contracts to purchase standard commercial COVID-19 vaccines with an adult indication. Offerors may propose vaccines or presentations that have received Emergency Use Authorization or Biologics License Application approval for individuals aged 19 years and older. The maximum ordering quantity is up to 30 million doses, with a minimum order of 100 doses. Proposals are due by December 13, 2022 by 5:00 pm Eastern Time. Award decisions are anticipated on or around January 17, 2023.
There is no set-aside designation. The solicitation falls under NAICS 325414 and PSC D399 with vaccines to be purchased for state and local immunization programs as outlined in Section 317(j) of the Public Health Service Act. Current contractors include major vaccine manufacturers with potential contract values estimated in the billions based on maximum order quantities and current vaccine prices. Vaccines will be delivered FOB destination to CDC distribution centers in the United States and performance will take place domestically.
Notice text
11 versions
Update #11 · Latest ·
Update (12/12/22): Please find attached Amendment 5 to the RFP. This amendment extends the due date for proposals to 5:00 pm ET on December 13, 2022.
Update (12/09/22): Please find attached Questions and Answers as of December 9, 2022. We've added one additional question and answer.
Update (12/02/22): Please find attached Amendment 4 to the RFP. This amendment extends the due date for proposals to 5:00 pm ET on December 12, 2022. Please note that this is intended to be the final extension to the due date for propoals, as it will be difficult to support further extensions while ensuring that the Government is timely prepared for the commercialization of COVID-19 vaccines.
Update (12/01/22): Please find attached Amendment 3 to the RFP. This amendment clarifies that CDC seeks to award contracts for all U.S.-licensed or authorized COVID-19 vaccine brands with an adult indication.
Update (11/30/22): Please find attached Questions and Answers as of November 30, 2022. With the closing of the question and answer period on November 29, 2022, this is expected to be the final version of the questions and answers document.
Update (11/28/22): Please find attached Questions and Answers as of November 28, 2022.
Update (11/23/22): Please find attached Questions and Answers as of November 23, 2022.
Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022.
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #10 ·
Update (12/09/22): Please find attached Questions and Answers as of December 9, 2022. We've added one additional question and answer.
Update (12/02/22): Please find attached Amendment 4 to the RFP. This amendment extends the due date for proposals to 5:00 pm ET on December 12, 2022. Please note that this is intended to be the final extension to the due date for propoals, as it will be difficult to support further extensions while ensuring that the Government is timely prepared for the commercialization of COVID-19 vaccines.
Update (12/01/22): Please find attached Amendment 3 to the RFP. This amendment clarifies that CDC seeks to award contracts for all U.S.-licensed or authorized COVID-19 vaccine brands with an adult indication.
Update (11/30/22): Please find attached Questions and Answers as of November 30, 2022. With the closing of the question and answer period on November 29, 2022, this is expected to be the final version of the questions and answers document.
Update (11/28/22): Please find attached Questions and Answers as of November 28, 2022.
Update (11/23/22): Please find attached Questions and Answers as of November 23, 2022.
Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022.
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #9 ·
Update (12/02/22): Please find attached Amendment 4 to the RFP. This amendment extends the due date for proposals to 5:00 pm ET on December 12, 2022. Please note that this is intended to be the final extension to the due date for propoals, as it will be difficult to support further extensions while ensuring that the Government is timely prepared for the commercialization of COVID-19 vaccines.
Update (12/01/22): Please find attached Amendment 3 to the RFP. This amendment clarifies that CDC seeks to award contracts for all U.S.-licensed or authorized COVID-19 vaccine brands with an adult indication.
Update (11/30/22): Please find attached Questions and Answers as of November 30, 2022. With the closing of the question and answer period on November 29, 2022, this is expected to be the final version of the questions and answers document.
Update (11/28/22): Please find attached Questions and Answers as of November 28, 2022.
Update (11/23/22): Please find attached Questions and Answers as of November 23, 2022.
Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022.
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #8 ·
Update (12/01/22): Please find attached Amendment 3 to the RFP. This amendment clarifies that CDC seeks to award contracts for all U.S.-licensed or authorized COVID-19 vaccine brands with an adult indication.
Update (11/30/22): Please find attached Questions and Answers as of November 30, 2022. With the closing of the question and answer period on November 29, 2022, this is expected to be the final version of the questions and answers document.
Update (11/28/22): Please find attached Questions and Answers as of November 28, 2022.
Update (11/23/22): Please find attached Questions and Answers as of November 23, 2022.
Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022.
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #7 ·
Update (11/30/22): Please find attached Questions and Answers as of November 30, 2022. With the closing of the question and answer period on November 29, 2022, this is expected to be the final version of the questions and answers document.
Update (11/28/22): Please find attached Questions and Answers as of November 28, 2022.
Update (11/23/22): Please find attached Questions and Answers as of November 23, 2022.
Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022.
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #6 ·
Update (11/28/22): Please find attached Questions and Answers as of November 28, 2022.
Update (11/23/22): Please find attached Questions and Answers as of November 23, 2022.
Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022.
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #5 ·
Update (11/23/22): Please find attached Questions and Answers as of November 23, 2022.
Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022.
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #4 ·
Update (11/22/22): Please find attached Questions and Answers as of November 22, 2022.
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #3 ·
Update (11/21/22): Please find attached (a) Questions and Answers as of November 21, 2022, and (b) Amendment 2 to the RFP. The due date for questions is extended to 5:00 pm ET on November 29, 2022, and the due date for proposals is extended to 5:00 pm ET on December 5, 2022.
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #2 ·
Update (11/18/22): Please find attached (a) Questions and Answers as of November 18, 2022, and (b) Amendment 1 to the RFP. The due date for proposals is extended to 5:00 pm ET on November 30, 2022.
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Update #1 ·
The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery indefinite quantity (IDIQ) contracts for the purchase of standard commercial COVID-19 vaccines with an adult indication. Offerors may propose any number of vaccines or presentations of Emergency Use Authorizations (EUA) and/or Biologics License Application (BLA) COVID-19 vaccines indicated for persons aged 19 and older.
Item Description and Quantities
COVID-19 Vaccine – Adult (age 19 years and older)
Maximum ordering quantity: Up to 30 million doses
Minimum ordering quantity: 100 doses
Min. Order Size: 100 Doses
Fed. Excise Tax: $0.75 per dose
Ordering period: One year from date of award
The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage.
The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs, and current and former U.S. territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.
Vaccines under this contract will be ordered through delivery orders in the Vaccine Tracking System (VTrckS). Orders shall be placed by CDC on behalf of eligible awardees, or by the awardees themselves. Contractors are required to interface with VTrckS. If unable to interface at the time of award, the vendor shall complete interface implementation no later than 3 months after contract award.
For refrigerated and frozen vaccines, the Contractor shall be required to deliver vaccines F.O.B. destination, as directed by delivery orders, to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN. For ultra-cold vaccines, the contractor shall provide delivery options for (a) the bulk delivery of vaccines F.O.B. destination to the CDC centralized distribution locations currently in Aurora, CO, and Memphis, TN, and (b) drop ship delivery of vaccines F.O.B. destination as directed by delivery orders to provider locations. In addition, shipments to five CDC Occupational Health Clinic locations may be requested by the CDC.
Offers shall be submitted by 4:30 pm Eastern time (ET) on November 28, 2022. Offers shall be submitted electronically (via e-mail) in Microsoft Word and/or Microsoft Excel files to Joshua Houston, Contract Specialist, pkf5@cdc.gov, and Pellumbeshe Hoxhaj, Contracting Officer, kfx2@cdc.gov. Offers shall reference RFP No. 75D301-22-R-72483.
Awards are anticipated to be made on or about January 17, 2023. This date may be changed by the Government without prior notice.
This acquisition will be conducted in accordance with FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. The solicitation and any amendments issued will be posted on www.sam.gov when issued. No hard copies of the solicitation and amendments will be mailed.
Any inquiries about this solicitation shall be submitted to Joshua Houston, Contract Specialist, at pkf5@cdc.gov. The deadline for questions to be submitted prior to the due date for proposals is November 22, 2022 at 4:30pm ET. The Government may not answer questions received after this date.
Files
Show all 14
Notice history
| Notice | Type | Posted |
|---|---|---|
| Adult COVID-19 Vaccines | Award Notice | |
| Adult COVID-19 Vaccines | Award Notice | |
| Adult COVID-19 Vaccines | Award Notice | |
| This notice | Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response | Office of the Assistant Secretary for Preparedness and Response | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity